SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (23498)7/24/1998 10:13:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
I'm not sure about the 2-3 NDAs in 1999. I assume that the 3 this year or early next year are oral and topical Targretin for CTCL and oral Panretin for KS. One additional NDA next year could be oral panretin for APL. The 1-2 more NDAs could be oral Targretin or Panretin for psoriasis. The other one could be oral Targretin or Panretin for one of the larger indications for cancer.



To: Machaon who wrote (23498)7/25/1998 1:04:00 PM
From: Doug Baer  Respond to of 32384
 
Bob and all,

I made a mistake in the previous post.
Ligand plans to file 3 NDAs in 1998-9 (which likely includes 1 in 1998 and 2 more in 1999). I apologize for the misunderstanding.

--db



To: Machaon who wrote (23498)7/26/1998 4:20:00 AM
From: Skeeter Bug  Read Replies (2) | Respond to of 32384
 
robert, what is happening over here at lgnd? seems to be nicely valued. any bad news? please provide a quick synopsis of the situation. tia...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News